Drug Discovery

Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar.

AstraZeneca, BenevolentAI join forces for AI-powered drug discovery

AstraZeneca has commenced a long-term collaboration with BenevolentAI to tap into the latter’s artificial intelligence (AI) and machine learning technology to accelerate discovery of new drugs for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Janssen to deploy Iktos’ AI solution to enhance small molecule drug discovery

French start-up company Iktos has entered into a research collaboration with Janssen Pharmaceutica to deploy its artificial intelligence (AI) technology to help the latter increase speed and efficiency of its small molecule drug discovery.

Aptorum launches Smart Pharma for computational repurposed drug discovery

Hong Kong-based Aptorum Group has established a new subsidiary group called Smart Pharma with a focus on discovering computational repurposed drugs to address orphan and unmet diseases.

FSD Pharma to acquire Prismic Pharmaceuticals

FSD Pharma and Prismic Pharmaceuticals have entered into a securities exchange agreement dated April 22, 2019 pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic.

Fulcrum acquires global rights of investigational drug losmapimod from GSK

Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK).

CASI Pharmaceuticals in-licenses rights to novel anti-CD38 monoclonal antibody program from Black Belt Therapeutics

CASI Pharmaceuticals has announced the signing of a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics.

SK Biopharmaceuticals, twoXAR collaborate to develop treatments for NSCLC

SK Biopharmaceuticals has collaborated with an artificial intelligence (AI)-driven biopharmaceutical firm twoXAR for the discovery and development of first-in-class treatments for non-small cell lung cancer (NSCLC).

LabCorp to buy Envigo’s non-clinical research services business in $485m deal

LabCorp’s Covance Drug Development segment is set to acquire Envigo’s non-clinical research services business, while Envigo’s Research Models Services business will purchase the Covance Research Products business.